Evidence map›Paper›PMID 34155526›Full record

ArticleCardiovascular and interventional radiology2021

A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective.

Nishath Altaf, Thathya Venu Ariyaratne, Adrian Peacock, Irene Deltetto, Jad El-Hoss, Shannon Thomas, Colman Taylor, Bibombe Patrice Mwipatayi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Nishath AltafDepartment of Vascular Surgery, Royal Perth Hospital, Royal Perth Bentley Group, Level 6, North Block, Wellington Street, Perth, WA, 6000, Australia. nishaltaf@gmail.com.
Thathya Venu AriyaratneBoston Scientific Corporation, Sydney, NSW, Australia.
Adrian PeacockHealth Technology Analysts, Sydney, NSW, Australia.
Irene DeltettoHealth Technology Analysts, Sydney, NSW, Australia.
Jad El-HossBoston Scientific Corporation, Sydney, NSW, Australia.
Shannon ThomasDepartment of Vascular Surgery, Prince of Wales Hospital, Sydney, NSW, Australia.
Colman TaylorHealth Technology Analysts, Sydney, NSW, Australia.
Bibombe Patrice MwipatayiDepartment of Vascular Surgery, Royal Perth Hospital, Royal Perth Bentley Group, Level 6, North Block, Wellington Street, Perth, WA, 6000, Australia.
Royal Perth Hospital · AUPrince of Wales Hospital · AUThe George Institute for Global Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeImprovement in long-term outcomes through innovative, cost-effective medical technologies is a focus for endovascular procedures aimed at treating symptomatic lower-limb peripheral arterial disease (PAD). The advent of drug-eluting stents (DES) has improved symptomatic PAD treatment via a reduction in high rates of target lesion revascularisation (TLR). The present study aimed to compare the 5-year financial impact of treatment with Eluvia, a new paclitaxel-eluting stent, versus treatment with Zilver PTX, a drug-coated stent, among patients in Australia by developing a budget impact model (BIM).

methodsA BIM was developed from an Australian public hospital payer perspective using Australian national cost weights (AUD), published literature, and public hospital audit data. Clinical outcomes, including clinically driven TLRs (CD-TLRs), adverse events, and length of stay, were based on the 2-year results of the IMPERIAL trial, which compared Eluvia DES to Zilver PTX.

resultsAssuming EVP eligibility rate of 80% and DES uses rate ranging from 10 to 28% (superficial femoral artery lesions only), the 5-year model forecasted a treatment population between 14,428 and 40,399 patients. The model estimated 1499-4198 fewer CD-TLRs and 16,515-46,243 fewer hospital days with Eluvia DES use. This translated to 5-year potential savings of $4.3-$12.1 million to the Australian public hospital payer attributable to reduced CD-TLRs for Eluvia DES and $33.1-$92.6 million to Australian public hospitals owing to reduced adverse events and hospital bed days.

conclusionEluvia DES use as treatment for symptomatic lower-limb PAD could lead to potential savings for the Australian public healthcare system based on improved patient outcomes.

Indexed as

Drug-Eluting StentsPeripheral Arterial DiseaseAustraliaFemoral ArteryHumansPaclitaxelPopliteal ArteryProsthesis DesignTreatment OutcomeVascular PatencyPaclitaxelBudget impact modelHealthcare system costsPaclitaxel-eluting stentPeripheral arterial diseaseSuperficial femoral arteryTarget lesion revascularisation

Identifiers

PMID34155526
PMCPMC8382623
OpenAlexW3174647733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.